Akero Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Akero Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2018 to Q3 2024.
  • Akero Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $7.47M, a 30.1% increase year-over-year.
  • Akero Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $28.6M, a 47.5% increase year-over-year.
  • Akero Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $21.5M, a 7.51% decline from 2022.
  • Akero Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $23.2M, a 131% increase from 2021.
  • Akero Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $10.1M, a 67% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $28.6M $7.47M +$1.73M +30.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $26.9M $7.66M +$2.86M +59.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $24.1M $7.4M +$2.55M +52.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $21.5M $6.12M +$2.08M +51.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $19.4M $5.74M -$5.99M -51.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 $25.4M $4.8M +$637K +15.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $24.8M $4.84M +$1.53M +46.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 $23.2M $4.04M +$1.4M +52.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $21.8M $11.7M +$9.12M +349% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $12.7M $4.16M +$1.73M +70.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $11M $3.31M +$947K +40.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $10.1M $2.64M +$725K +37.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $9.33M $2.61M +$1.07M +69% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 $8.26M $2.44M +$1.11M +84.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 $7.15M $2.36M +$1.13M +91.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $6.02M $1.92M +$1.25M +186% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-25
Q3 2020 $4.78M $1.55M +$1.06M +220% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $3.71M $1.32M +$920K +229% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 $2.79M $1.24M +$1.02M +475% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $1.77M $670K Oct 1, 2019 Dec 31, 2019 10-K 2022-02-25
Q3 2019 $483K +$449K +1321% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $402K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 $215K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q3 2018 $34K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.